Symbols / TARA Stock $4.76 +9.68% Protara Therapeutics, Inc.
TARA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Ratings
Current target
$4.76
Low
$24.00
High
$30.00
Mean
$26.14
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-20 | main | Oppenheimer | Outperform → Outperform | $28 |
| 2026-05-14 | main | JP Morgan | Overweight → Overweight | $26 |
| 2026-04-29 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2026-03-04 | init | JP Morgan | — → Overweight | $27 |
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2026-01-07 | init | Piper Sandler | — → Overweight | $24 |
| 2025-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-11-19 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-05-22 | init | Jones Trading | — → Buy | $21 |
| 2025-04-28 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-04-16 | init | Scotiabank | — → Sector Outperform | $12 |
| 2025-03-14 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-03-11 | init | LifeSci Capital | — → Outperform | $22 |
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-12-06 | reit | Guggenheim | Buy → Buy | $20 |
| 2024-12-06 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-08-12 | main | Oppenheimer | Outperform → Outperform | $25 |
| 2024-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
- Cancer and rare disease biotech Protara in TD Cowen oncology webcast May 26 - Stock Titan Wed, 20 May 2026 12
- H.C. Wainwright reiterates Protara stock rating citing LM data - Investing.com Wed, 20 May 2026 11
- Protara Therapeutics to Host Virtual Webinar on Lymphatic Malformations and TARA-002 Clinical Program - Quiver Quantitative Mon, 18 May 2026 12
- Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study - Benzinga Fri, 15 May 2026 15
- Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus Wed, 20 May 2026 12
- Inside Protara’s May 19 webinar on lymphatic malformations and TARA-002 - Stock Titan Mon, 18 May 2026 12
- Cantor Fitzgerald reiterates Protara Therapeutics stock rating - Investing.com Wed, 20 May 2026 12
- Protara Therapeutics (TARA) Unveils Promising Phase 2 Trial Resu - GuruFocus Fri, 15 May 2026 18
- Bladder cancer trial update from 31 patients goes to urology meeting - Stock Titan Mon, 27 Apr 2026 07
- Bladder cancer drug TARA-002 shows 55% complete response at 12 months - Stock Titan Fri, 15 May 2026 11
- TARA Maintained by JP Morgan -- Price Target Lowered to $26.00 - GuruFocus hu, 14 May 2026 21
- Janus Henderson (TARA) disclosed 5.21M-share, 9.6% stake in Protara - Stock Titan Fri, 15 May 2026 16
- Biotech Protara funds TARA-002 programs into 2028, targets 2027 biologics filing - Stock Titan Wed, 13 May 2026 12
- BlackRock (TARA) reports 3,387,459 shares, 6.3% stake (Schedule 13G) - Stock Titan Mon, 27 Apr 2026 07
- Protara Therapeutics (Nasdaq: TARA) posts Q1 loss and details TARA-002 plans - Stock Titan Wed, 13 May 2026 12
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
64.55
+31.32%
|
49.15
+12.70%
|
43.61
+16.16%
|
37.55
|
| Research And Development |
|
42.63
+34.47%
|
31.70
+26.87%
|
24.99
+48.67%
|
16.81
|
| Selling General And Administration |
|
21.92
+25.59%
|
17.45
-6.30%
|
18.62
-10.19%
|
20.74
|
| General And Administrative Expense |
|
21.92
+25.59%
|
17.45
-6.30%
|
18.62
-10.19%
|
20.74
|
| Other Gand A |
|
21.92
+25.59%
|
17.45
-6.30%
|
18.62
-10.19%
|
20.74
|
| Total Expenses |
|
64.55
+31.32%
|
49.15
+12.70%
|
43.61
+16.16%
|
37.55
|
| Operating Income |
|
-64.55
-31.32%
|
-49.15
-12.70%
|
-43.61
-16.16%
|
-37.55
|
| Total Operating Income As Reported |
|
-64.55
-31.32%
|
-49.15
-12.70%
|
-43.61
+34.97%
|
-67.06
|
| EBITDA |
|
-64.19
-31.47%
|
-48.82
-12.83%
|
-43.27
+32.98%
|
-64.57
|
| Normalized EBITDA |
|
-64.24
-31.47%
|
-48.86
-12.88%
|
-43.28
-23.43%
|
-35.07
|
| Reconciled Depreciation |
|
0.36
+9.04%
|
0.33
-2.64%
|
0.34
+37.50%
|
0.25
|
| EBIT |
|
-64.55
-31.32%
|
-49.15
-12.70%
|
-43.61
+32.71%
|
-64.81
|
| Total Unusual Items |
|
0.05
+36.11%
|
0.04
+200.00%
|
0.01
+100.04%
|
-29.50
|
| Total Unusual Items Excluding Goodwill |
|
0.05
+36.11%
|
0.04
+200.00%
|
0.01
+100.04%
|
-29.50
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-29.52
|
| Impairment Of Capital Assets |
|
—
|
—
|
0.00
-100.00%
|
29.52
|
| Net Income |
|
-57.44
-28.80%
|
-44.60
-10.33%
|
-40.42
+38.71%
|
-65.95
|
| Pretax Income |
|
-57.44
-28.80%
|
-44.60
-10.33%
|
-40.42
+38.71%
|
-65.95
|
| Net Non Operating Interest Income Expense |
|
6.33
+53.11%
|
4.13
+29.99%
|
3.18
+191.03%
|
1.09
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
1.14
|
| Net Interest Income |
|
6.33
+53.11%
|
4.13
+29.99%
|
3.18
+191.03%
|
1.09
|
| Interest Expense |
|
—
|
—
|
—
|
1.14
|
| Interest Income Non Operating |
|
6.33
+53.11%
|
4.13
+29.99%
|
3.18
+42.65%
|
2.23
|
| Interest Income |
|
6.33
+53.11%
|
4.13
+29.99%
|
3.18
+42.65%
|
2.23
|
| Other Income Expense |
|
0.78
+84.16%
|
0.42
+3425.00%
|
0.01
+100.04%
|
-29.50
|
| Other Non Operating Income Expenses |
|
0.73
+88.63%
|
0.39
|
—
|
—
|
| Gain On Sale Of Security |
|
0.05
+36.11%
|
0.04
+200.00%
|
0.01
-29.41%
|
0.02
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-57.44
-28.80%
|
-44.60
-10.33%
|
-40.42
+38.71%
|
-65.95
|
| Net Income From Continuing Operation Net Minority Interest |
|
-57.44
-28.80%
|
-44.60
-10.33%
|
-40.42
+38.71%
|
-65.95
|
| Net Income From Continuing And Discontinued Operation |
|
-57.44
-28.80%
|
-44.60
-10.33%
|
-40.42
+38.71%
|
-65.95
|
| Net Income Continuous Operations |
|
-57.44
-28.80%
|
-44.60
-10.33%
|
-40.42
+38.71%
|
-65.95
|
| Normalized Income |
|
-57.49
-28.80%
|
-44.63
-10.39%
|
-40.43
-10.92%
|
-36.45
|
| Net Income Common Stockholders |
|
-57.44
-28.80%
|
-44.60
-10.33%
|
-40.42
+38.71%
|
-65.95
|
| Diluted EPS |
|
—
|
-2.17
+39.22%
|
-3.57
+39.08%
|
-5.86
|
| Basic EPS |
|
—
|
-2.17
+39.22%
|
-3.57
+39.08%
|
-5.86
|
| Basic Average Shares |
|
—
|
20.59
+81.73%
|
11.33
+0.64%
|
11.26
|
| Diluted Average Shares |
|
—
|
20.59
+81.73%
|
11.33
+0.64%
|
11.26
|
| Diluted NI Availto Com Stockholders |
|
-57.44
-28.80%
|
-44.60
-10.33%
|
-40.42
+38.71%
|
-65.95
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
78.95
|
| Current Assets |
|
68.70
|
| Cash Cash Equivalents And Short Term Investments |
|
65.58
|
| Cash And Cash Equivalents |
|
39.59
|
| Other Short Term Investments |
|
25.99
|
| Receivables |
|
0.24
|
| Accrued Interest Receivable |
|
0.24
|
| Prepaid Assets |
|
2.85
|
| Restricted Cash |
|
—
|
| Other Current Assets |
|
0.04
|
| Total Non Current Assets |
|
10.25
|
| Net PPE |
|
6.56
|
| Gross PPE |
|
7.38
|
| Accumulated Depreciation |
|
-0.82
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
0.60
|
| Other Properties |
|
6.23
|
| Leases |
|
0.55
|
| Goodwill And Other Intangible Assets |
|
2.66
|
| Goodwill |
|
—
|
| Other Intangible Assets |
|
2.66
|
| Investments And Advances |
|
0.00
|
| Non Current Prepaid Assets |
|
0.27
|
| Other Non Current Assets |
|
0.76
|
| Total Liabilities Net Minority Interest |
|
10.63
|
| Current Liabilities |
|
6.15
|
| Payables And Accrued Expenses |
|
3.05
|
| Payables |
|
2.43
|
| Accounts Payable |
|
2.43
|
| Current Accrued Expenses |
|
0.62
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.11
|
| Total Tax Payable |
|
—
|
| Current Debt And Capital Lease Obligation |
|
0.98
|
| Current Capital Lease Obligation |
|
0.98
|
| Total Non Current Liabilities Net Minority Interest |
|
4.48
|
| Long Term Debt And Capital Lease Obligation |
|
4.48
|
| Long Term Capital Lease Obligation |
|
4.48
|
| Stockholders Equity |
|
68.32
|
| Common Stock Equity |
|
68.32
|
| Capital Stock |
|
0.01
|
| Common Stock |
|
0.01
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
11.36
|
| Ordinary Shares Number |
|
11.36
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
268.73
|
| Retained Earnings |
|
-200.38
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.03
|
| Other Equity Adjustments |
|
-0.03
|
| Total Equity Gross Minority Interest |
|
68.32
|
| Total Capitalization |
|
68.32
|
| Working Capital |
|
62.56
|
| Invested Capital |
|
68.32
|
| Total Debt |
|
5.47
|
| Capital Lease Obligations |
|
5.47
|
| Net Tangible Assets |
|
65.66
|
| Tangible Book Value |
|
65.66
|
| Available For Sale Securities |
|
—
|
| Investmentin Financial Assets |
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-56.37
-57.41%
|
-35.81
+4.66%
|
-37.56
-41.95%
|
-26.46
|
| Cash Flow From Continuing Operating Activities |
|
-56.37
-57.41%
|
-35.81
+4.66%
|
-37.56
-41.95%
|
-26.46
|
| Net Income From Continuing Operations |
|
-57.44
-28.80%
|
-44.60
-10.33%
|
-40.42
+38.71%
|
-65.95
|
| Depreciation Amortization Depletion |
|
0.36
+9.04%
|
0.33
-2.64%
|
0.34
+37.50%
|
0.25
|
| Depreciation |
|
0.36
+9.04%
|
0.33
-2.64%
|
0.34
+37.50%
|
0.25
|
| Depreciation And Amortization |
|
0.36
+9.04%
|
0.33
-2.64%
|
0.34
+37.50%
|
0.25
|
| Other Non Cash Items |
|
1.08
+7.14%
|
1.01
-0.39%
|
1.01
-25.84%
|
1.37
|
| Stock Based Compensation |
|
3.83
-7.25%
|
4.12
-32.29%
|
6.09
-8.91%
|
6.69
|
| Asset Impairment Charge |
|
—
|
—
|
0.00
-100.00%
|
29.52
|
| Operating Gains Losses |
|
-0.01
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-0.01
|
—
|
—
|
—
|
| Change In Working Capital |
|
-2.94
-173.40%
|
4.01
+196.81%
|
-4.14
-867.90%
|
0.54
|
| Change In Prepaid Assets |
|
-2.09
-265.37%
|
1.26
+199.76%
|
-1.26
-577.36%
|
0.27
|
| Change In Payables And Accrued Expense |
|
-0.05
-101.28%
|
4.06
+1082.80%
|
0.34
-75.13%
|
1.38
|
| Change In Accrued Expense |
|
0.82
-69.32%
|
2.68
+629.90%
|
-0.51
-167.51%
|
0.75
|
| Change In Payable |
|
-0.87
-163.22%
|
1.38
+62.85%
|
0.85
+34.39%
|
0.63
|
| Change In Account Payable |
|
-0.87
-163.22%
|
1.38
+62.85%
|
0.85
+34.39%
|
0.63
|
| Change In Other Current Assets |
|
0.32
+198.17%
|
-0.33
+85.74%
|
-2.30
-1136.04%
|
0.22
|
| Change In Other Current Liabilities |
|
-1.12
-14.23%
|
-0.98
-7.31%
|
-0.92
+30.90%
|
-1.33
|
| Investing Cash Flow |
|
-139.49
-828.22%
|
19.16
-63.93%
|
53.11
+255.23%
|
14.95
|
| Cash Flow From Continuing Investing Activities |
|
-139.49
-828.22%
|
19.16
-63.93%
|
53.11
+255.23%
|
14.95
|
| Net PPE Purchase And Sale |
|
-0.09
-49.21%
|
-0.06
-40.00%
|
-0.04
+62.50%
|
-0.12
|
| Purchase Of PPE |
|
-0.09
-49.21%
|
-0.06
-40.00%
|
-0.04
+62.50%
|
-0.12
|
| Capital Expenditure |
|
-0.09
-49.21%
|
-0.06
-40.00%
|
-0.04
+62.50%
|
-0.12
|
| Net Investment Purchase And Sale |
|
-139.40
-825.35%
|
19.22
-63.84%
|
53.15
+252.70%
|
15.07
|
| Purchase Of Investment |
|
-204.63
-596.45%
|
-29.38
-141.11%
|
-12.19
+72.02%
|
-43.55
|
| Sale Of Investment |
|
65.23
+34.23%
|
48.60
-25.62%
|
65.34
+11.46%
|
58.62
|
| Financing Cash Flow |
|
82.72
-40.86%
|
139.87
+153797.80%
|
-0.09
-1.11%
|
-0.09
|
| Cash Flow From Continuing Financing Activities |
|
82.72
-40.86%
|
139.87
+153797.80%
|
-0.09
-1.11%
|
-0.09
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
—
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
80.96
-40.47%
|
136.01
|
0.00
+100.00%
|
-0.09
|
| Common Stock Payments |
|
—
|
—
|
-0.09
-1.11%
|
-0.09
|
| Repurchase Of Capital Stock |
|
—
|
—
|
-0.09
-1.11%
|
-0.09
|
| Proceeds From Stock Option Exercised |
|
2.55
-35.31%
|
3.94
|
0.00
|
—
|
| Net Other Financing Charges |
|
-0.80
-862.65%
|
-0.08
+8.79%
|
-0.09
|
—
|
| Changes In Cash |
|
-113.14
-191.83%
|
123.21
+697.02%
|
15.46
+233.30%
|
-11.60
|
| Beginning Cash Position |
|
163.54
+305.50%
|
40.33
+62.15%
|
24.87
-31.80%
|
36.47
|
| End Cash Position |
|
50.40
-69.18%
|
163.54
+305.50%
|
40.33
+62.15%
|
24.87
|
| Free Cash Flow |
|
-56.46
-57.39%
|
-35.87
+4.60%
|
-37.60
-41.48%
|
-26.58
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Amortization Of Securities |
|
-1.25
-81.75%
|
-0.69
-54.28%
|
-0.44
-139.05%
|
1.14
|
| Common Stock Issuance |
|
80.96
-40.47%
|
136.01
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
80.96
-40.47%
|
136.01
|
0.00
|
—
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-13 View
- 8-K2026-05-13 View
- 42026-04-09 View
- 42026-04-02 View
- 8-K2026-03-30 View
- 10-K2026-03-10 View
- 8-K2026-03-10 View
- 8-K2026-02-24 View
- 42026-01-27 View
- 42026-01-27 View
- 42026-01-27 View
- 42026-01-27 View
- 42026-01-22 View
- 42026-01-22 View
- 42026-01-22 View
- 42026-01-22 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
- 42026-01-21 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|